Biosoft aims to become a conductor between fundamental science and services. It helps business representatives to find appropriate scientific partners.
VISION AND MISSION
Biosoft aims to put on stream fundamental science problems that phramaceutical and other lifesciences companies are forced to deal with in order to get a desired result.
The BioUML platform is certified and intellectual rights on it totally belong to the Biosoft company
Biosoft is totally responsible for the quality of all of the services it provides.
Our top management team unites experts in science and administration, that's why Biosoft is developing quickly and efficiently.
Biosoft has collected a team of real experts to grant you top quality scientific services.
The Genome Enhancer prospective drug target identification pipeline was highly evaluated by the attendees of the past TRI-CON 2020 exhibition in San Francisco. We have received lots of positive feedback regarding our tool and the perspective of its application in the biomedical research field.
According to an independent comparison, our platform was recognized as the most accurate and fast SBML simulator based on a set of 613 curated models from BioModels database.
We have received lots of extremely valuable feedback on improving our system for the needs of medical doctors while showing Genome Enhancer to real oncologists at this huge congress. It was truly great to receive all these comments full of excitement from the world’s most advanced doctors!
Pharmaceutical companies now tend to give some stages of the drug discovery process to outsourcing. But the choice of a Contract Research Organization (CRO) is not an easy task. There is a certain amount of criteria for making this choice: it is price, time and quality of the result. The main criterion is actually the ability to use the received result in further stages of research. All existing CROs just provide stand-alone services to their clients without actually solving their customer’s global problem. Pharmaceutical companies are forced to find different CROs and to give them different parts of their problem. Then they have to gather somehow all the intermediate results and try to move on. But if we take into account the fact that there are almost no CROs in the world that could solve the fundamental scientific problems of finding the therapeutic target and compound, it becomes clear that pharmaceutical companies are forced to either have their own bioinformatics groups (which is very expensive), or give these tasks on outsourcing to honored organizations like MIT, which can certainly solve these problems but the prices for their services are enormously high because they don’t put such investigations on a stream and each time they solve a singular problem. The Biosoft project aims to stop this negative trend.
Biosoft aims to open an internet science services exchange market which would allow any CRO or academic institution to find clients for research orders and pharmaceutical companies to find scientific partners. The bioinformatics problems will solved via the BioUML platform, which has already been developed and which lays in the basis of Biosoft current services list. At the moment Biosoft has opened registration for all the CROs and academic institutions that want to become our partners. Once a necessary number of partners will be gathered, Biosoft will start its internet science services exchange project. At the current moment Biosoft presents data analysis services which are listed on the PRODUCTS AND SERVICES tab. We really hope that you become our client or a science partner. If you have any questions, please contact us via the ASK A QUESTION form on this web site or via e-mail at firstname.lastname@example.org. We are really looking forward to cooperating with you!